Gliclazide + Metformin is a potent fixed-dose combination designed for effective management of Type 2 Diabetes Mellitus. It combines Gliclazide, a sulfonylurea that stimulates insulin release from the pancreas, and Metformin, a biguanide that improves insulin sensitivity and reduces hepatic glucose production. This dual-action therapy offers superior glycemic control, especially when monotherapy is insufficient. The Metformin component may include a prolonged-release formulation to enhance tolerability and sustained effect. By lowering high blood sugar levels, Gliclazide + Metformin helps reduce long-term complications such as neuropathy, retinopathy, and cardiovascular disease, supporting comprehensive diabetes care.

Gliclazide + Metformin is a leading prescription medication for effective, long-term control of blood glucose in adults with

It is typically prescribed when monotherapy, especially with Metformin alone, does not sufficiently control blood sugar. This fixed-dose combination contains two complementary agents: Gliclazide, a sulfonylurea that stimulates the pancreas to release insulin, and Metformin, a biguanide that lowers hepatic glucose production while enhancing peripheral insulin sensitivity. Gliclazide addresses insulin secretion defects, while Metformin targets insulin resistance. The Metformin component is often prolonged-release for steady effects and improved gut tolerance. Together, they provide comprehensive glycemic control, helping to maintain target HbA1c levels and reduce risks of diabetes complications such as neuropathy, retinopathy, and cardiovascular disease. Strict adherence to the prescribed dosing regimen is essential for optimal management of this chronic, progressive condition.

Primarily prescribed for adults with Type 2 Diabetes Mellitus when diet, exercise, and monotherapy fail to control blood sugar adequately.

• Used in patients who initially responded to single-agent therapy but later experienced worsening glucose control.

• Helps achieve intensive glycemic control to reach target HbA1c levels rapidly.

• Aims to prevent or slow the progression of diabetic complications such as neuropathy, retinopathy, and cardiovascular diseases.

• Combines two complementary actions: Gliclazide stimulates insulin release from the pancreas, while Metformin lowers glucose production and increases insulin sensitivity.

• Provides better and sustained blood sugar control compared to either drug alone.

• Reduces the risk of weight gain that is often seen with sulfonylurea monotherapy due to Metformin's effect.

• Simplifies treatment with a convenient single tablet, improving patient compliance.

• Contributes to an improved cardiovascular risk profile.

Patients taking Gliclazide + Metformin should be monitored for side effects from both Gliclazide and Metformin components:

• Hypoglycemia (low blood sugar) is the most common risk, with symptoms like sweating, shaking, palpitations, dizziness, and confusion.

• Gastrointestinal issues such as diarrhoea, nausea, vomiting, and abdominal discomfort are usually related to Metformin and may be reduced by taking the medication with food or using the prolonged-release formulation.

• Metallic taste in the mouth and headache are possible side effects.

• Mild skin reactions may occur.

• Rare but serious: Lactic acidosis, a dangerous build-up of lactic acid, causing severe tiredness, muscle pain, and difficulty breathing. Immediate medical help is necessary.

• Long-term Metformin use may cause Vitamin B12 deficiency, potentially leading to neuropathy and anaemia.

• Take Gliclazide + Metformin exactly as prescribed, usually once or twice daily.

• Swallow tablets whole with water; do not crush or chew.

• Always take with food, preferably the main daily meal, to reduce hypoglycemia and GI side effects.

Gliclazide + Metformin treats Type 2 Diabetes Mellitus through two complementary actions:

• Glimepiride (Sulfonylurea): Stimulates insulin release by binding to ATP-sensitive potassium channels on pancreatic beta cells, causing cell depolarization and calcium influx, which triggers insulin vesicle release into the bloodstream. This leads to a rapid reduction of blood glucose, especially after meals.

• Metformin (Biguanide): Activates AMP-activated protein kinase (AMPK), resulting in decreased liver glucose production (gluconeogenesis), enhanced glucose uptake in peripheral tissues, and modestly reduced intestinal glucose absorption, improving overall insulin sensitivity.

• Always take Gliclazide + Metformin with your main meal to enhance effectiveness and reduce side effects.

• Carry fast-acting sugar like glucose tablets or juice to treat potential hypoglycemia caused by Gliclazide.

• Inform all healthcare providers, including dentists and radiologists, that you are using this medication, especially before scans or surgeries.

• Watch for infection signs and symptoms of lactic acidosis (muscle pain, fatigue).

• Do not stop the medication abruptly without consulting your doctor.

• Lactic Acidosis Risk: Metformin-related risk is high in patients with severe kidney disease, liver disease, or heavy alcohol use. Stop medication if you experience severe muscle pain, fatigue, or rapid breathing.

• Hypoglycemia Risk: Glimepiride can cause low blood sugar, especially at treatment start, increased doses, or missed meals. Learn to recognise and treat symptoms promptly.

• Contrast Media: Stop Metformin before and 48 hours after iodinated contrast procedures; restart after a kidney function check.

• Vitamin B12 Deficiency: Monitor periodically during long-term use.

• Surgery/Illness: Temporarily stop medication during serious illness or before major surgery.

• Store in original packaging at room temperature, below 30°C.

• Protect from moisture, heat, and direct sunlight.

• Keep away from children and pets.

• Check expiry and dispose of unused medication responsibly.

• Gliclazide + Metformin must be taken with food for the best effect.

• Avoid alcohol completely to reduce severe risks of hypoglycemia and lactic acidosis.

• Never skip meals when taking the medicine, as Glimepiride stimulates insulin release regardless of food intake, increasing hypoglycemia risk.

• Excessive carbohydrate intake may undermine blood sugar control; maintain a balanced diet.

• Discuss potassium intake with your doctor if you have kidney issues, since Metformin depends on renal clearance.

• Hypoglycemia risk increases with co-administered antidiabetic drugs, NSAIDs, some antibiotics, and beta-blockers (which may mask hypoglycemia symptoms).

• Metformin levels may rise with iodinated contrast agents (temporary hold), carbonic anhydrase inhibitors, and some cationic drugs.

• Corticosteroids, diuretics, thyroid hormones, and oral contraceptives may reduce blood sugar control effectiveness.

• Contraindicated in severe renal impairment (eGFR < 30) due to lactic acidosis risk.

• Use cautiously or avoid in severe liver disease due to impaired lactate clearance.

• Avoid in acute heart failure, recent heart attack, or shock due to tissue hypoxia, as it increases the risk of lactic acidosis.

• G6PD deficiency patients are at risk of hemolytic anaemia from sulfonylureas.

The typical daily dose of Gliclazide + Metformin is one tablet, taken once or twice daily with meals. The exact dosing regimen depends on your blood sugar control, response to treatment, and kidney function. Due to the high potency of Gliclazide and the specific requirements for Metformin, sticking strictly to your prescribed dose is essential. Dose adjustments should always be done under medical supervision.

If a dose is missed, take it immediately if it is within a few hours before the next scheduled dose and with a meal. If near the next dose (within 4–6 hours), skip the missed dose and continue routine dosing. Never double the dose to compensate, as it heightens hypoglycemia and gastrointestinal side effect risks. Discuss adherence concerns with your healthcare provider.